Know Cancer

or
forgot password

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors


N/A
18 Years
N/A
Not Enrolling
Both
Cervical Cancer, HEENT Cancer, Renal Cancer, Uterine Cancer, CERVIX UTERI NOS, RECTUM

Thank you

Trial Information

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors


Inclusion Criteria:



- Patients must have locally advanced cancer as determined by currently accepted
diagnostic work-up, including CT/MR/US.

- KPS >70%.

- Patients must be > or equal to 18 years of age.

Exclusion Criteria:

- Patients will be excluded from the study if they fulfill any of the following
criteria:

- Patients with abnormal baseline thyroid function tests, or any thyroid disorder
including but not limited to hypothyroidism and thyroiditis. Patients with thyroid
cancer who have had a thyroidectomy are not excluded.

- Patients who are pregnant or lactating.

- Mental impairment that may compromise the ability to give informed consent and comply
with the requirements of the study.

- Patients who cannot tolerate being in the PET scanner for the duration of the study.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To describe imaging findings in human cancer with the new hypoxia tracer 124IAZGP and PET/CT

Outcome Time Frame:

at least once at approximately 6 hours and/or 24 hours after radiotracer administration.

Safety Issue:

No

Principal Investigator

Heiko Schöder, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

05-023

NCT ID:

NCT00588276

Start Date:

June 2005

Completion Date:

June 2012

Related Keywords:

  • Cervical Cancer
  • HEENT Cancer
  • Renal Cancer
  • Uterine Cancer
  • CERVIX UTERI NOS
  • RECTUM
  • measurable disease
  • locally advanced disease
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Uterine Cervical Neoplasms
  • Uterine Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021